Digital rectal examination in prostate cancer screening at PSA level 3.0-3.9 ng/ml: long-term results from a randomized trial

References

• Culp MB, Soerjomataram I, Efstathiou JA, et al. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38–52.
   PubMed Web of Science ®Google Scholar
• Bleyer A, Spreafico F, Barr R. Prostate cancer in young men: an emerging young adult and older adolescent challenge. Cancer. 2020;126(1):46–57.
   PubMed Web of Science ®Google Scholar
• Bergstralh EJ, Roberts RO, Farmer SA, et al. Population-based case-control study of PSA and DRE screening on prostate cancer mortality. Urology. 2007;70(5):936–941.
   PubMed Web of Science ®Google Scholar
• Ilic D, Djulbegovic M, Jung JH, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018;362:k3519.
   PubMed Web of Science ®Google Scholar
• Hugosson J, Roobol MJ, Månsson M, et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur Urol. 2019;76(1):43–51.
   PubMed Web of Science ®Google Scholar
• Tsodikov A, Gulati R, Heijnsdijk EAM, et al. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med. 2017;3167(7):449–455.
   PubMed Web of Science ®Google Scholar
• Fenton JJ, Weyrich MS, Durbin S, et al. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US preventive services task force. JAMA. 2018;319(18):1914–1931.
   PubMed Web of Science ®Google Scholar
• Weinmann S, Richert-Boe K, Glass AG, et al. Prostate cancer screening and mortality: a case-control study (United States). Cancer Causes Control. 2004;15(2):133–138.
   PubMed Web of Science ®Google Scholar
• Concato J, Wells CK, Horwitz RI, et al. The effectiveness of screening for prostate cancer: a nested case-control study. Arch Intern Med. 2006;166(1):38–43.
   PubMedGoogle Scholar
• Agalliu I, Weiss NS, Lin DW, et al. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men. Cancer Causes Control. 2007;18(9):931–937.
   PubMed Web of Science ®Google Scholar
• Andriole GL, Crawford ED, Grubb RL, 3rd, PLCO Project Team, et al. Prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up. J Natl Cancer Inst. 2012;104(2):125–132.
   PubMedGoogle Scholar
• Harvey CJ, Pilcher J, Richenberg J, et al. Applications of transrectal ultrasound in prostate cancer. Br J Radiol. 2012;85(1):S3–S17.
   PubMedGoogle Scholar
• Richert-Boe KE, Humphrey LL, Glass AG, et al. Screening digital rectal examination and prostate cancer mortality: a case-control study. J Med Screen. 1998;5(2):99–103.
   PubMed Web of Science ®Google Scholar
• Naji L, Randhawa H, Sohani Z, et al. Digital rectal examination for prostate cancer screening in primary care: a systematic review and meta-analysis. Ann Fam Med. 2018;16(2):149–154.
   PubMed Web of Science ®Google Scholar
• Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 2017;197(2S):S200–S207.
   PubMedGoogle Scholar
• Tan GH, Nason G, Ajib K, et al. Smarter screening for prostate cancer. World J Urol. 2019;37(6):991–999.
   PubMed Web of Science ®Google Scholar
• Chiu PK, Ng CF, Semjonow A, et al. A multicentre evaluation of the role of the prostate health index (PHI) in regions with differing prevalence of prostate cancer: adjustment of PHI reference ranges is needed for European and Asian settings. Eur Urol. 2019;75(4):558–561.
   PubMed Web of Science ®Google Scholar
• Tomlins SA, Day JR, Lonigro RJ, et al. Urine TMPRSS2:ERG plus PCA3 for individualized prostate cancer risk assessment. Eur Urol. 2016;70(1):45–53.
   PubMed Web of Science ®Google Scholar
• Mottet N, Bellmunt J, Briers E, et al. EAU – ESTRO – ESUR – SIOG guidelines on prostate cancer. Edn. presented at the EAU annual congress Milan. Arnhem: EAU Guidelines Office; 2021.
   Google Scholar
• Issa MM, Zasada W, Ward K, et al. The value of digital rectal examination as a predictor of prostate cancer diagnosis among United States veterans referred for prostate biopsy. Cancer Detect Prev. 2006;30(3):269–275.
   PubMedGoogle Scholar
• Poyet C, Nieboer D, Bhindi B, et al. Prostate cancer risk prediction using the novel versions of the European randomised study for screening of prostate cancer (ERSPC) and prostate cancer prevention trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort. BJU Int. 2016;117(3):401–408.
   PubMed Web of Science ®Google Scholar
• Halpern JA, Oromendia C, Shoag JE, et al. Use of digital rectal examination as an adjunct to prostate specific antigen in the detection of clinically significant prostate cancer. J Urol. 2018;199(4):947–953.
   PubMed Web of Science ®Google Scholar
• Schröder FH, van der Maas P, Beemsterboer P, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European randomized study of screening for prostate cancer. J Natl Cancer Inst. 1998;90(23):1817–1823.
   PubMedGoogle Scholar
• Gosselaar C, Roobol MJ, van den Bergh RC, et al. Digital rectal examination and the diagnosis of prostate cancer-a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. Eur Urol. 2009;55(1):139–146.
   PubMed Web of Science ®Google Scholar
• Gosselaar C, Roobol MJ, Roemeling S, et al. Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics. Prostate. 2007;67(2):154–161.
   PubMed Web of Science ®Google Scholar
• Christensson A, Björk T, Nilsson O, et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993;150(1):100–105.
   PubMed Web of Science ®Google Scholar
• Reissigl A, Klocker H, Pointner J, et al. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. Urology. 1996;48(6):62–66.
   PubMedGoogle Scholar
• Stenman UH, Leinonen J, Alfthan H, et al. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991;51(1):222–226.
   PubMed Web of Science ®Google Scholar
• Stenman UH, Hakama M, Knekt P, et al. Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer. Lancet. 1994;344(8937):1594–1598.
   PubMed Web of Science ®Google Scholar
• Jacobsen SJ, Bergstralh EJ, Katusic SK, et al. Screening digital rectal examination and prostate cancer mortality: a population-based case-control study. Urology. 1998;52(2):173–179.
   PubMed Web of Science ®Google Scholar
• Patel AR, Klein EA. Risk factors for prostate cancer. Nat Clin Pract Urol. 2009;6(2):87–95.
   PubMedGoogle Scholar